As the weight-loss drug market expands beyond U.S. borders, investors are shifting focus to international growth opportunities. While Eli Lilly faced stock declines ahead of earnings concerns about Foundayo's U.S. performance, the bigger story lies in overseas markets where obesity affects over one billion people globally.

Novo Nordisk demonstrated this international momentum with 44% growth in obesity-drug sales outside the U.S. during the first quarter, compared to just 9% growth in the more mature American market. This rapid international expansion suggests companies are successfully tapping into previously untreated patient populations.

Despite impressive growth, both Novo Nordisk and Lilly currently treat less than 2% of the global obesity population, indicating substantial room for expansion. The international weight-loss drug market represents a critical revenue stream that investors may have previously overlooked in their focus on U.S. prescription trends.